Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


One-dose “morning after” pill?

This article was originally published in The Tan Sheet

Executive Summary

HRA Pharma currently is conducting its own studies on one-dose levonorgestrel 1.5 mg drug for emergency contraception to be submitted to FDA in early 2004, the Paris-based firm says. HRA Pharma says it is not sure whether the NDA will be submitted for Rx or OTC status, but noted it likely would be difficult to switch OTC from Rx in light of FDA's recent "not approvable" letter to Barr Labs (1"The Tan Sheet" May 10, 2003, p. 5). Barr's current EC regimen includes two pills of levonorgestrel .75 mg taken 12 hours apart...

You may also be interested in...

Plan B OTC Submission Fails On Lack Of Data In Teens

Barr Labs will continue to work with FDA toward approval of emergency contraceptive Plan B (levonorgestrel .75 mg) for OTC use, the company said in a May 6 statement

QUOTED. 19 April 2021. Jeff Shuren & William Maisel

Two top officials in the US FDA’s device center are warning of delays in the agency’s review of submissions for new products that aren’t directly tied to the coronavirus pandemic.

Breakthrough Therapy Designations At US FDA Stay Sluggish In 2021

With 12 new BTDs announced so far this year, 2021 is on pace to match the COVID-19-depressed total number of designations in 2020. Here’s a breakdown of the candidates that have received the designation.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts